Base Editing- Rewriting DNA One Letter at a Time | GeneInCell | 2026

Silencing Genetic Disease with shRNA | GeneInCell | 2026

shRNA is a gene-silencing tool that uses the cell’s own RNA interference machinery to reduce harmful protein production. In this episode, we explore how short hairpin RNAs are designed to target specific mutant genes, how they are delivered into cells, and why they hold promise for treating genetic disease through long-lasting gene knockdown.

Base Editing- Rewriting DNA One Letter at a Time | GeneInCell | 2026

Base editing is changing the future of gene editing by allowing scientists to rewrite DNA one letter at a time. In this episode, we explore how base editors work, why they offer a more precise alternative to traditional CRISPR cutting, and how they are being used to correct disease-causing mutations. We also look at their growing potential in research and medicine, along with the challenges that remain for safe and effective clinical use.

siRNAs: Programmable Drugs for Silencing Genetic Disease | GeneInCell

siRNAs are transforming medicine by acting as programmable drugs that selectively silence disease-causing genes. In this episode, we explore how small interfering RNAs work through the RNA interference pathway, why they are so powerful for precision therapeutics, and how they are being developed to treat genetic, metabolic, liver, and rare diseases. We also discuss delivery challenges, clinical progress, and what makes siRNA one of the most promising platforms in modern drug development.

Prime editing: Search and replace for human DNA | GeneInCell | 2026

Prime editing is a next-generation gene editing tool designed to precisely rewrite DNA—like a search-and-replace function for the human genome. In this episode, we break down how prime editing works, the chemistry behind it, and why it offers a powerful alternative to traditional CRISPR by making targeted changes without creating double-strand breaks. We also explore its applications in disease correction, its growing path toward the clinic, and the key challenges that still stand in the way.

New Approach Methodologies (NAMs) for Replacing Animal Models in Drug Discovery | GeneInCell | 2026

NAMs are changing how new drugs are developed. We discuss organoids, tissue chips, and AI-based tools, along with the growing FDA and NIH push toward more human-relevant methods that can improve prediction, reduce reliance on animal models, and help bring safer treatments forward faster.